2023
ScRNA-seq defines dynamic T-cell subsets in longitudinal colon and peripheral blood samples in immune checkpoint inhibitor-induced colitis
Mann J, Lucca L, Austin M, Merkin R, Robert M, Al Bawardy B, Raddassi K, Aizenbud L, Joshi N, Hafler D, Abraham C, Herold K, Kluger H. ScRNA-seq defines dynamic T-cell subsets in longitudinal colon and peripheral blood samples in immune checkpoint inhibitor-induced colitis. Journal For ImmunoTherapy Of Cancer 2023, 11: e007358. PMID: 37586769, PMCID: PMC10432652, DOI: 10.1136/jitc-2023-007358.Peer-Reviewed Original ResearchMeSH KeywordsColitisHumansImmune Checkpoint InhibitorsSingle-Cell Gene Expression AnalysisSkin NeoplasmsT-Lymphocyte SubsetsConceptsImmune checkpoint inhibitorsT cell subsetsCheckpoint inhibitorsImmune environmentImmune checkpoint inhibitor-induced colitisCheckpoint inhibitor-induced colitisPeripheral immune environmentsStages of colitisTreatment of colitisMerkel cell carcinomaT cell populationsPeripheral blood samplesCourse of progressionT cell receptorMultiple tumor typesAlternative cancer therapyCommon toxicitiesICI colitisTreatment discontinuationAdverse eventsBiologic therapyImmune suppressionCell carcinomaColitisBlood samples
2021
Immune Checkpoint Inhibitor–associated Diarrhea and Colitis: A Systematic Review and Meta-analysis of Observational Studies
Tran AN, Wang M, Hundt M, Chugh R, Ohm J, Grimshaw A, Ciarleglio M, Hung KW, Proctor DD, Price CC, Laine L, Al-Bawardy B. Immune Checkpoint Inhibitor–associated Diarrhea and Colitis: A Systematic Review and Meta-analysis of Observational Studies. Journal Of Immunotherapy 2021, 44: 325-334. PMID: 34380976, DOI: 10.1097/cji.0000000000000383.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Cortex HormonesBiological ProductsColitisDiarrheaHumansImmune Checkpoint InhibitorsIncidenceNeoplasmsObservational Studies as TopicConceptsImmune checkpoint inhibitorsDiarrhea/colitisICI therapyCheckpoint inhibitorsObservational studyAnti-programmed cell death-1/Outcomes of ICISystematic reviewCell death-1/Permanent ICI discontinuationReal-world incidenceRemission of diarrheaRecurrence of symptomsDeath-1/Treatment of diarrheaRandom-effects modelICI discontinuationAdvanced malignanciesAppropriate patientsPrimary outcomeOverall incidenceAntigen-4Early treatmentColitisHigh risk